JPM 2022: Abbott, iRhythm, Novocure, Zimmer Biomet
Executive Summary
The annual J.P. Morgan Healthcare Conference includes presentations from major medtech companies describing their experience in 2021 and expectations for 2022 as they continue to cope with the impact of the Omicron surge. Here are some of the highlights from the presentations on the second day of the meeting.
You may also be interested in...
Exec Chat: New iRhythm CEO Foresees Enormous Opportunity In AI For Arrhythmia Detection
Quentin Blackford, who recently became iRhythm’s CEO after serving as Dexcom’s chief operating officer, talked to Medtech Insight about the challenges and opportunities in the emerging remote cardiac monitoring market.
Biden Promises 500 Million COVID-19 Tests As Omicron Threatens To Overwhelm US Health Care System
The “President’s Winter Plan” to fight the new variant includes mailing out free COVID-19 take-home tests to Americans who ask for it. AdvaMed says it will encourage manufacturers to keep producing tests.
The Post-COVID Mantra For Medtechs: Prioritize, Optimize And Modernize
Medtech’s resilience and flexibility have been clear to see during the COVID-19 pandemic. In this forward-looking view for 2022, CEOs from some of the Top 50 global medtechs share their perspectives on the present and the future, from company and health care system standpoints.